<p>澳大利亞市場正處於謹慎階段，交易者暫停以評估近期的波動性和即將發佈的重要財報。對於願意探索知名股票之外的投資者來説，便士股票——通常代表較小或較新的公司——可以提供引人注目的機會。儘管這個術語的含義有些過時，但當這些股票具備強大的財務基礎和增長潛力時，仍然可以提供可觀的價值。</p>
<h3>澳大利亞十大便士股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>Alfabs Australia (ASX:AAL)</td>
<td>A$0.45</td>
<td>A$128.96M</td>
<td>✅ 4 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Dusk Group (ASX:DSK)</td>
<td>A$0.825</td>
<td>A$51.37M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>IVE Group (ASX:IGL)</td>
<td>A$2.88</td>
<td>A$442.63M</td>
<td>✅ 4 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>MotorCycle Holdings (ASX:MTO)</td>
<td>A$3.62</td>
<td>A$267.18M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>West African Resources (ASX:WAF)</td>
<td>A$3.04</td>
<td>A$3.47B</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Bravura Solutions (ASX:BVS)</td>
<td>A$2.32</td>
<td>A$1.04B</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Praemium (ASX:PPS)</td>
<td>A$0.785</td>
<td>A$375.56M</td>
<td>✅ 5 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Service Stream (ASX:SSM)</td>
<td>A$2.20</td>
<td>A$1.35B</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Fleetwood (ASX:FWD)</td>
<td>A$2.57</td>
<td>A$237.93M</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>GWA Group (ASX:GWA)</td>
<td>A$2.40</td>
<td>A$629.76M</td>
<td>✅ 5 ⚠️ 1 查看分析</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們 ASX 便士股票篩選器中的 411 只股票的完整列表。</p>
<p>以下是篩選器中的一些選擇。</p>
<h2>Cobre (ASX:CBE)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Cobre Limited 參與澳大利亞和博茨瓦納的礦產資源勘探和評估，市值為 A$49.18 百萬。</p>
<p><strong>運營：</strong> 公司的收入完全來自勘探活動，金額為 A$0.35 百萬。</p>
<p><strong>市值：</strong> A$49.18M</p>
<p>Cobre Limited 專注於在澳大利亞和博茨瓦納的礦產勘探，尚未產生收入，勘探活動收入為 A$0.35 百萬。公司無債務，但面臨挑戰，截止 2025 年 6 月 30 日的年度淨虧損為 A$2.12 百萬。儘管在過去五年中每年減少虧損 7.9%，但審計師對 Cobre 的財務穩定性表示質疑，認為其持續經營能力存在風險。最近通過股權融資籌集的 A$700 萬可能提供短期緩解，但突顯了持續的流動性壓力和股東稀釋的擔憂，儘管管理團隊經驗豐富。</p>
<ul>
<li>點擊探索我們在 Cobre 財務健康報告中的詳細發現。</li>
<li>通過查看我們的歷史業績報告，獲取 Cobre 的歷史結果的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d4b0dfcf-6a6c-4bc4-866c-0cddb9ddf808/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d4b0dfcf-6a6c-4bc4-866c-0cddb9ddf808/chart/financial-position-analysis"/></p>
<p>ASX:CBE 財務狀況分析截至 2025 年 11 月</p>
<h2>SKS Technologies Group (ASX:SKS)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> SKS Technologies Group Limited 在澳大利亞運營，專注於音頻視覺、電氣和通信產品及服務的設計、供應和安裝，市值為 A$388.86 百萬。</p>
<p><strong>運營：</strong> 該公司在照明和音頻視覺市場的運營中產生了 A$261.66 百萬的收入。</p>
<p><strong>市值：</strong> A$388.86M</p>
<p>SKS Technologies Group 展示了強勁的財務表現，過去一年收益增長 111.8%，超過行業平均水平。公司無債務，保持健康的資產負債表，短期資產超過短期和長期負債。SKS 的股本回報率高達 57.2%，反映出對股東資金的高效管理。然而，近期內部人士的大量拋售可能對潛在投資者構成擔憂。儘管如此，SKS 宣佈截至 2025 年 6 月 30 日的每股派息 A$0.05，表明其對持續盈利和現金流生成能力的信心，儘管每週波動穩定。</p>
<ul>
<li>解鎖我們對 SKS Technologies Group 股票分析的全面見解，查看此財務健康報告。</li>
<li>查看我們的增長表現報告，以獲取 SKS Technologies Group 未來的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/671ce2bc-92e2-4b23-9582-6699d498e1cc/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/671ce2bc-92e2-4b23-9582-6699d498e1cc/chart/financial-position-analysis"/></p>
<p>ASX:SKS 財務狀況分析截至 2025 年 11 月</p>
<h2>Starpharma Holdings (ASX:SPL)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Starpharma Holdings Limited 是一家生物製藥公司，專注於全球藥物和醫療保健應用的樹枝狀聚合物技術的研究、開發和商業化，市值為 A$175.65 百萬。</p>
<p><strong>運營：</strong> 該公司通過樹枝狀聚合物的發現、開發和商業化產生了 A$5.85 百萬的收入。</p>
<p><strong>市值：</strong> A$175.65M</p>
<p>Starpharma Holdings 的市值為 A$175.65 百萬，正在利用其樹枝狀聚合物技術在生物製藥領域中航行。儘管尚未盈利且股價波動較大，但 Starpharma 的短期資產超過其負債，提供了一定的財務穩定性。最近與 Genentech 和 Radiopharm 的合作突顯了戰略伙伴關係，這可能通過里程碑付款和特許權使用費增強未來的收入來源，儘管當前收入僅為 A$6 百萬。管理團隊的平均任期相對較短，僅為 1.8 年，表明近期的領導變動可能會影響未來在這一高風險領域的戰略方向。</p>
<ul>
<li>通過我們的全面資產負債表健康報告，深入瞭解 Starpharma Holdings 的複雜性。</li>
<li>通過我們的公司收益預估報告，獲取 Starpharma Holdings 的前景和預期表現的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2b323321-8904-4741-a853-0e7a90dcce93/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2b323321-8904-4741-a853-0e7a90dcce93/chart/debt-equity-history-analysis"/></p>
<p>截至 2025 年 11 月，ASX:SPL 的債務與股本歷史及分析</p>
<h2>抓住機會</h2>
<ul>
<li>點擊此鏈接訪問 411 只 ASX 便士股票的完整範圍。</li>
<li>對其他可能性感興趣？通過投資可靠的分紅股票來多樣化您的投資組合，以應對潛在的市場波動。</li>
</ul>
<p><em>這篇文章來自 Simply Wall St，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成購買或出售任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>

<p>澳大利亞市場保持謹慎，交易者正在評估波動性和財報。便士股票，通常是較小或較新的公司，提供了引人注目的機會。值得注意的股票包括 Cobre Limited、SKS Technologies Group 和 Starpharma Holdings，它們各自具有獨特的財務狀況和增長潛力。Cobre 面臨流動性挑戰，SKS 表現出強勁的財務業績，而 Starpharma 則在探索樹狀聚合物技術。投資者可以探索 411 只 ASX 便士股票，以實現多樣化和潛在增長</p>

<p>The Australian market is experiencing a cautious phase, with traders pausing to assess recent volatility and upcoming significant earnings reports. For investors willing to explore beyond well-known stocks, penny stocks—typically representing smaller or newer companies—can offer intriguing opportunities. Despite the term's outdated connotations, these stocks can provide substantial value when they possess strong financial foundations and potential for growth.</p>
<div class="lb-trans"><p>澳大利亞市場正處於謹慎階段，交易者暫停以評估近期的波動性和即將發佈的重要財報。對於願意探索知名股票之外的投資者來説，便士股票——通常代表較小或較新的公司——可以提供引人注目的機會。儘管這個術語的含義有些過時，但當這些股票具備強大的財務基礎和增長潛力時，仍然可以提供可觀的價值。</p>
</div><h3>Top 10 Penny Stocks In Australia</h3>
<div class="lb-trans"><h3>澳大利亞十大便士股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>Alfabs Australia (ASX:AAL)</td>
<td>A$0.45</td>
<td>A$128.96M</td>
<td>✅ 4 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Dusk Group (ASX:DSK)</td>
<td>A$0.825</td>
<td>A$51.37M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>IVE Group (ASX:IGL)</td>
<td>A$2.88</td>
<td>A$442.63M</td>
<td>✅ 4 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>MotorCycle Holdings (ASX:MTO)</td>
<td>A$3.62</td>
<td>A$267.18M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>West African Resources (ASX:WAF)</td>
<td>A$3.04</td>
<td>A$3.47B</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Bravura Solutions (ASX:BVS)</td>
<td>A$2.32</td>
<td>A$1.04B</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Praemium (ASX:PPS)</td>
<td>A$0.785</td>
<td>A$375.56M</td>
<td>✅ 5 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Service Stream (ASX:SSM)</td>
<td>A$2.20</td>
<td>A$1.35B</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Fleetwood (ASX:FWD)</td>
<td>A$2.57</td>
<td>A$237.93M</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>GWA Group (ASX:GWA)</td>
<td>A$2.40</td>
<td>A$629.76M</td>
<td>✅ 5 ⚠️ 1 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>Alfabs Australia (ASX:AAL)</td>
<td>A$0.45</td>
<td>A$128.96M</td>
<td>✅ 4 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Dusk Group (ASX:DSK)</td>
<td>A$0.825</td>
<td>A$51.37M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>IVE Group (ASX:IGL)</td>
<td>A$2.88</td>
<td>A$442.63M</td>
<td>✅ 4 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>MotorCycle Holdings (ASX:MTO)</td>
<td>A$3.62</td>
<td>A$267.18M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>West African Resources (ASX:WAF)</td>
<td>A$3.04</td>
<td>A$3.47B</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Bravura Solutions (ASX:BVS)</td>
<td>A$2.32</td>
<td>A$1.04B</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Praemium (ASX:PPS)</td>
<td>A$0.785</td>
<td>A$375.56M</td>
<td>✅ 5 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Service Stream (ASX:SSM)</td>
<td>A$2.20</td>
<td>A$1.35B</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Fleetwood (ASX:FWD)</td>
<td>A$2.57</td>
<td>A$237.93M</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>GWA Group (ASX:GWA)</td>
<td>A$2.40</td>
<td>A$629.76M</td>
<td>✅ 5 ⚠️ 1 查看分析</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 411 stocks from our ASX Penny Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們 ASX 便士股票篩選器中的 411 只股票的完整列表。</p>
</div><p>Here's a peek at a few of the choices from the screener.</p>
<div class="lb-trans"><p>以下是篩選器中的一些選擇。</p>
</div><h2>Cobre (ASX:CBE)</h2>
<div class="lb-trans"><h2>Cobre (ASX:CBE)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Cobre Limited is involved in the exploration and evaluation of mineral properties in Australia and Botswana, with a market cap of A$49.18 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Cobre Limited 參與澳大利亞和博茨瓦納的礦產資源勘探和評估，市值為 A$49.18 百萬。</p>
</div><p><strong>Operations:</strong> The company's revenue segment is solely derived from exploration activities, amounting to A$0.35 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入完全來自勘探活動，金額為 A$0.35 百萬。</p>
</div><p><strong>Market Cap:</strong> A$49.18M</p>
<div class="lb-trans"><p><strong>市值：</strong> A$49.18M</p>
</div><p>Cobre Limited, focused on mineral exploration in Australia and Botswana, remains pre-revenue with A$0.35 million from exploration activities. The company is debt-free but faces challenges with a net loss of A$2.12 million for the year ending June 30, 2025. Despite reducing losses by 7.9% annually over five years, Cobre's financial stability is questioned by its auditors regarding its ability to continue as a going concern. Recent capital raises totaling A$7 million through equity offerings may provide short-term relief but highlight ongoing liquidity pressures and shareholder dilution concerns amidst an experienced management team.</p>
<div class="lb-trans"><p>Cobre Limited 專注於在澳大利亞和博茨瓦納的礦產勘探，尚未產生收入，勘探活動收入為 A$0.35 百萬。公司無債務，但面臨挑戰，截止 2025 年 6 月 30 日的年度淨虧損為 A$2.12 百萬。儘管在過去五年中每年減少虧損 7.9%，但審計師對 Cobre 的財務穩定性表示質疑，認為其持續經營能力存在風險。最近通過股權融資籌集的 A$700 萬可能提供短期緩解，但突顯了持續的流動性壓力和股東稀釋的擔憂，儘管管理團隊經驗豐富。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in Cobre's financial health report.</li>
<li>Gain insights into Cobre's historical outcomes by reviewing our past performance report.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊探索我們在 Cobre 財務健康報告中的詳細發現。</li>
<li>通過查看我們的歷史業績報告，獲取 Cobre 的歷史結果的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d4b0dfcf-6a6c-4bc4-866c-0cddb9ddf808/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/d4b0dfcf-6a6c-4bc4-866c-0cddb9ddf808/chart/financial-position-analysis"/></p>
<p>ASX:CBE Financial Position Analysis as at Nov 2025</p>
<div class="lb-trans"><p>ASX:CBE 財務狀況分析截至 2025 年 11 月</p>
</div><h2>SKS Technologies Group (ASX:SKS)</h2>
<div class="lb-trans"><h2>SKS Technologies Group (ASX:SKS)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> SKS Technologies Group Limited operates in Australia, focusing on the design, supply, and installation of audio visual, electrical, and communication products and services with a market cap of A$388.86 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> SKS Technologies Group Limited 在澳大利亞運營，專注於音頻視覺、電氣和通信產品及服務的設計、供應和安裝，市值為 A$388.86 百萬。</p>
</div><p><strong>Operations:</strong> The company generates revenue of A$261.66 million from its operations in the lighting and audio-visual markets.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司在照明和音頻視覺市場的運營中產生了 A$261.66 百萬的收入。</p>
</div><p><strong>Market Cap:</strong> A$388.86M</p>
<div class="lb-trans"><p><strong>市值：</strong> A$388.86M</p>
</div><p>SKS Technologies Group has demonstrated strong financial performance, with earnings growing 111.8% over the past year, surpassing industry averages. The company is debt-free and maintains a healthy balance sheet, with short-term assets exceeding both short- and long-term liabilities. SKS's return on equity is outstanding at 57.2%, reflecting efficient management of shareholder funds. However, significant insider selling in recent months could be a concern for potential investors. Despite this, SKS declared a dividend of A$0.05 per share for the year ended June 30, 2025, indicating confidence in its ongoing profitability and cash flow generation capabilities amidst stable weekly volatility.</p>
<div class="lb-trans"><p>SKS Technologies Group 展示了強勁的財務表現，過去一年收益增長 111.8%，超過行業平均水平。公司無債務，保持健康的資產負債表，短期資產超過短期和長期負債。SKS 的股本回報率高達 57.2%，反映出對股東資金的高效管理。然而，近期內部人士的大量拋售可能對潛在投資者構成擔憂。儘管如此，SKS 宣佈截至 2025 年 6 月 30 日的每股派息 A$0.05，表明其對持續盈利和現金流生成能力的信心，儘管每週波動穩定。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of SKS Technologies Group stock in this financial health report.</li>
<li>Review our growth performance report to gain insights into SKS Technologies Group's future.</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖我們對 SKS Technologies Group 股票分析的全面見解，查看此財務健康報告。</li>
<li>查看我們的增長表現報告，以獲取 SKS Technologies Group 未來的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/671ce2bc-92e2-4b23-9582-6699d498e1cc/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/671ce2bc-92e2-4b23-9582-6699d498e1cc/chart/financial-position-analysis"/></p>
<p>ASX:SKS Financial Position Analysis as at Nov 2025</p>
<div class="lb-trans"><p>ASX:SKS 財務狀況分析截至 2025 年 11 月</p>
</div><h2>Starpharma Holdings (ASX:SPL)</h2>
<div class="lb-trans"><h2>Starpharma Holdings (ASX:SPL)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Starpharma Holdings Limited is a biopharmaceutical company focused on the research, development, and commercialization of dendrimer technology for pharmaceutical and healthcare applications globally, with a market cap of A$175.65 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Starpharma Holdings Limited 是一家生物製藥公司，專注於全球藥物和醫療保健應用的樹枝狀聚合物技術的研究、開發和商業化，市值為 A$175.65 百萬。</p>
</div><p><strong>Operations:</strong> The company generates revenue of A$5.85 million from the discovery, development, and commercialization of dendrimers.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司通過樹枝狀聚合物的發現、開發和商業化產生了 A$5.85 百萬的收入。</p>
</div><p><strong>Market Cap:</strong> A$175.65M</p>
<div class="lb-trans"><p><strong>市值：</strong> A$175.65M</p>
</div><p>Starpharma Holdings, with a market cap of A$175.65 million, is navigating the biopharmaceutical landscape with its dendrimer technology. Despite being unprofitable and having volatile share prices, Starpharma's short-term assets surpass its liabilities, providing some financial stability. Recent collaborations with Genentech and Radiopharm highlight strategic partnerships that could enhance future revenue streams through milestone payments and royalties, although current revenues are limited at A$6 million. The management team has a relatively short average tenure of 1.8 years, suggesting recent leadership changes which might influence strategic direction moving forward in this high-risk sector.</p>
<div class="lb-trans"><p>Starpharma Holdings 的市值為 A$175.65 百萬，正在利用其樹枝狀聚合物技術在生物製藥領域中航行。儘管尚未盈利且股價波動較大，但 Starpharma 的短期資產超過其負債，提供了一定的財務穩定性。最近與 Genentech 和 Radiopharm 的合作突顯了戰略伙伴關係，這可能通過里程碑付款和特許權使用費增強未來的收入來源，儘管當前收入僅為 A$6 百萬。管理團隊的平均任期相對較短，僅為 1.8 年，表明近期的領導變動可能會影響未來在這一高風險領域的戰略方向。</p>
</div><ul>
<li>Navigate through the intricacies of Starpharma Holdings with our comprehensive balance sheet health report here.</li>
<li>Gain insights into Starpharma Holdings' outlook and expected performance with our report on the company's earnings estimates.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過我們的全面資產負債表健康報告，深入瞭解 Starpharma Holdings 的複雜性。</li>
<li>通過我們的公司收益預估報告，獲取 Starpharma Holdings 的前景和預期表現的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2b323321-8904-4741-a853-0e7a90dcce93/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/2b323321-8904-4741-a853-0e7a90dcce93/chart/debt-equity-history-analysis"/></p>
<p>ASX:SPL Debt to Equity History and Analysis as at Nov 2025</p>
<div class="lb-trans"><p>截至 2025 年 11 月，ASX:SPL 的債務與股本歷史及分析</p>
</div><h2>Seize The Opportunity</h2>
<div class="lb-trans"><h2>抓住機會</h2>
</div><ul>
<li>Access the full spectrum of 411 ASX Penny Stocks by clicking on this link.</li>
<li>Interested In Other Possibilities? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊此鏈接訪問 411 只 ASX 便士股票的完整範圍。</li>
<li>對其他可能性感興趣？通過投資可靠的分紅股票來多樣化您的投資組合，以應對潛在的市場波動。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章來自 Simply Wall St，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成購買或出售任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div>

3 只市值低於 4 億澳元的 ASX 便士股值得關注